Anti-Alpha-V Immunoliposome Composition, Methods, and Uses

• US 20090196913A1
• Filed: 05/12/2008
• Published: 08/06/2009
• Est. Priority Date: 05/11/2007
• Status: Abandoned Application

• Current Assignee: Anthony Huang, Ken Shi Kun Huang, Linda A. Snyder, Steve P. Weng
• Original Assignee: Anthony Huang, Ken Shi Kun Huang, Linda A. Snyder, Steve P. Weng
• Inventors: Huang, Ken Shi Kun, Snyder, Linda A., Weng, Steve P., Huang, Anthony
• Application Number:
  US12/119,012
• Publication Number:
  US 20090196913A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

An immunoliposome composition targeted to the alpha-V-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha-V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or a the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

Claims

1. An anti-alpha-V targeted immunoliposome composition, comprising

liposomes comprised of vesicle-forming lipids and a conjugate comprised of a hydrophobic moiety, a hydrophilic polymer, and an anti-alpha-V antibody-derived construct having binding affinity for alpha V integrin subunit, said liposomes prior to in vivo administration having fewer than 25 antibodies per liposome.

2. The composition of claim 1, wherein said liposome having an entrapped drug.

3. The composition of claim 2, wherein said drug is an anthracycline antibiotic.

4. The composition of claim 3, wherein said anthracycline antibiotic is doxorubicin.

5. The composition of claim 1, wherein said liposomes prior to in vivo administration having about 15 antibodies per liposome.

6. A method of treating a condition characterized by cells that express at least one alpha-V-integrin receptor, comprising:

administering immunoliposomes according to claim 1.

7. The method of claim 6, wherein said condition is characterized by cells that express one or both of α

vβ

3 and α

5β

5 and which condition is a neoplastic disease.

8. The method of claim 7, wherein said neoplastic disease is melanoma.

9. The method of claim 6, wherein said administering comprises administering immunoliposomes further comprising an entrapped therapeutic agent.